Join the 'Ferric Citrate' group to help and get support from people like you.
Ferric Citrate News
Posted 17 Nov 2014 by Drugs.com
NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) – Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the trade name Auryxia (ferric citrate) for its FDA-approved ferric citrate. Auryxia, an iron-based phosphate binder, was approved by the FDA to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis in September 2014. Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are excited to receive FDA approval of the trade name Auryxia. We look forward to launching Auryxia in the U.S. at year end and to providing nephrologists with an effective phosphate binder for dialysis-dependent CKD patients." For more information about Auryxia, please visit www.Auryxia.com. About End Stage ... Read more